Psilocybin Legal Status by State

If you ask a simple question — is psilocybin legal? — you will get a simple answer that is also incomplete. Under federal law, psilocybin is a Schedule I controlled substance, classified alongside heroin as having no accepted medical use and a high potential for abuse. That classification is legally binding at the federal level and has not changed. What has changed, significantly and rapidly since 2019, is the patchwork of state and local laws that exists beneath it.

The legal landscape for psilocybin in America in 2026 is the most fragmented and the most rapidly evolving it has ever been. Two states have licensed therapy programs operating right now. A third has signed legislation and is building its regulatory framework. A fourth signed a hospital-based pilot program into law this January. Several more have active bills moving through their legislatures. Dozens of cities have decriminalized possession. And a presidential executive order signed on April 18th, 2026 has created a pathway toward federal rescheduling that did not exist six months ago.

This guide maps all of it, clearly and accurately, so you understand what is legal where — and what that actually means in practice.

Federal Law: The Baseline That Everything Else Sits On

Psilocybin has been a Schedule I substance under the Controlled Substances Act since October 27th, 1970. Schedule I is the most restrictive classification in federal drug law — it designates a substance as having no currently accepted medical use, a high potential for abuse, and insufficient safety data to permit use under medical supervision. The practical effect is that possession, distribution, and manufacture of psilocybin are federal crimes regardless of what any state law says.

That federal baseline matters because it means that even in states with legal or decriminalized frameworks, individuals can theoretically be prosecuted under federal law. In practice, federal enforcement against individual users in states with decriminalization measures is rare, but the risk is not zero and the legal exposure is real. Understanding that distinction — between what state law permits and what federal law prohibits — is essential context for everything that follows.

The federal picture shifted meaningfully on April 18th, 2026, when President Trump signed an executive order directing the FDA to fast-track psychedelic therapies for PTSD, depression, and addiction, and directing the attorney general to initiate rescheduling reviews for any Schedule I psychedelic that completes Phase 3 clinical trials. Psilocybin is among the substances named. The order does not change the current Schedule I status, but it creates a direct, expedited pipeline from successful clinical trial to rescheduling review — a pathway that has historically been slow enough to stall momentum entirely.

Oregon: The First and Most Developed Program

Oregon is where the modern American psilocybin access story begins. In November 2020, Oregon voters passed Measure 109, making the state the first in the country to legalize supervised psilocybin services. The law created a licensed service center model: individuals 21 and older can purchase, consume, and experience psilocybin under the supervision of a licensed facilitator at an approved service center. Personal possession outside that framework was decriminalized separately under Measure 110, passed the same night.

The Oregon Health Authority has been issuing licenses and the program has been operational since 2023. Service centers are concentrated in Portland and the Willamette Valley, though availability has been expanding. A session at a licensed Oregon service center typically runs several hundred to over a thousand dollars, depending on the facilitator and the length of the experience, and health insurance does not cover it. Personal cultivation for home use is not permitted under Measure 109 — the law covers supervised service center access only.

Oregon’s program is the most mature in the country and has become a reference point for every other state designing its own framework. Its strengths — licensed facilitators, regulated service centers, a formal preparation and integration structure — are also its limitations for many people. Access is structured, intentional, and not inexpensive.

Colorado: Decriminalization Plus a Regulated Framework

Colorado took a different approach when voters passed Proposition 122 in November 2022. The measure did two things simultaneously: it decriminalized the possession, growing, and sharing of psilocybin and several other natural psychedelics for personal use by adults 21 and older, and it created a licensed healing center model similar in some respects to Oregon’s service center framework.

The decriminalization component of Colorado’s law is broader than Oregon’s. Adults can legally possess and cultivate psilocybin mushrooms for personal use — not just access them through a licensed center. Gifting between adults is also permitted, though commercial sale outside of licensed healing centers is not. The healing center program, overseen by Colorado’s Department of Regulatory Agencies, has been operational and expanding its licensed facilities through 2025 and into 2026. Colorado’s framework also allows for integration with other mental health services in ways Oregon’s does not, including the possibility of combining supervised psilocybin experiences with licensed psychotherapy at the same clinic.

New Mexico and New Jersey: The Newest Legal Access Points

New Mexico signed medical psilocybin legislation into law and is currently building its regulatory framework. The program is expected to be operational by December 2026, according to current reporting. New Mexico’s approach is distinct in one important way: state courts have previously ruled that growing psilocybin mushrooms for personal use does not constitute “manufacturing” a controlled substance under New Mexico law — a legal interpretation that makes the state’s posture toward personal cultivation more permissive than most.

New Jersey became the first state to embed psilocybin therapy within a hospital system when Governor Murphy signed a pilot program bill into law on January 21st, 2026. The program allocates $6 million across three hospitals in different geographic regions, each receiving $2 million to develop and operate supervised psilocybin therapy programs. An 11-member advisory board oversees outcomes and will advise on future policy expansion. New Jersey’s hospital-based model is being watched closely as a potential template for states that want to integrate psilocybin therapy into existing healthcare infrastructure rather than creating a parallel system of stand-alone service centers.

Cities and Counties: Local Decriminalization Across Multiple States

Below the state level, a significant number of cities and counties have taken independent action to deprioritize psilocybin enforcement. These local measures do not change state or federal law, but they direct local law enforcement to treat personal possession as a low priority and, in some cases, eliminate local penalties entirely.

In California, Denver was actually the first city in the country to decriminalize psilocybin back in 2019 — though Denver is in Colorado, not California. Within California, Oakland, Santa Cruz, and several other cities have passed decriminalization measures. The state as a whole has not yet passed statewide decriminalization despite multiple attempts, including a 2024 ballot initiative that failed with 57% voting no.

In Massachusetts, several cities have taken local decriminalization action. Washington state has seen movement at both the city level — Olympia and Tacoma passed measures in 2024 and 2025 respectively — and at the county level, with King County voting in March 2026 to deprioritize personal psychedelic use and support continued research. Michigan and Washington D.C. also have local decriminalization in place in various jurisdictions.

States With Active Legislation in 2026

Beyond the states that have already acted, a substantial number are actively considering legislation. Connecticut’s Senate voted in April 2026 to expand the state’s psychedelics pilot program in anticipation of potential FDA approval. Minnesota has an advancing legalization bill. Bills have been introduced in New York, Nevada, and several other states as of April 2026, though none have yet passed into law.

Texas, despite its reputation as a conservative state, committed $50 million to ibogaine research last year under Governor Abbott — a figure the new federal executive order is designed to match. That investment signals that psychedelic research has bipartisan political support in ways that pure recreational legalization does not, and it suggests that the research-to-therapy pipeline may move forward in states that would never support broader decriminalization.

States with active research programs or pending legislation as of this writing include Connecticut, Maryland, Texas, Utah, Georgia, Illinois, Kansas, New York, Pennsylvania, Virginia, and West Virginia. In all of these states, psilocybin remains illegal for personal use — the activity is at the legislative and research level, not yet at the access level.

States Where Psilocybin Remains Fully Illegal

The majority of U.S. states have no decriminalization measures, no active therapy programs, and no significant legislative movement toward either. In these states — which include Alabama, Alaska, Arizona, Arkansas, Delaware, Florida, Hawaii, Idaho, Indiana, Iowa, Kentucky, Louisiana, Maine, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, North Carolina, North Dakota, Ohio, Oklahoma, Rhode Island, South Carolina, South Dakota, Tennessee, Vermont, Wisconsin, and Wyoming — possession of psilocybin remains a criminal offense under state law, with penalties that range from misdemeanor charges to felony prosecution depending on the amount involved and the specific statutes in place.

Florida is worth a specific mention: Governor DeSantis signed House Bill 651 into law in 2025, making Florida the fourth state to specifically ban even psilocybin mushroom spores — which, because they contain no psilocybin until germination, are legal to possess in 46 other states for microscopy and research purposes. Florida’s spore ban is one of the most restrictive positions in the country.

Where This Is All Heading

The direction of travel is clear, even if the destination and timeline are not. The number of states with some form of legal or decriminalized framework has grown every year since 2019. The clinical evidence supporting psilocybin’s therapeutic value — particularly for treatment-resistant depression and PTSD — continues to accumulate at institutions including Johns Hopkins, Stanford, and Harvard. The FDA has granted Breakthrough Therapy designation to psilocybin, which is the agency’s formal acknowledgment that preliminary evidence suggests it may offer substantial improvement over existing treatments.

Industry analysts and researchers are projecting potential FDA approval of a synthetic psilocybin compound — Compass Pathways’ COMP360 is the leading candidate — in late 2026 or early 2027. If that approval comes through, it would represent the first classic psychedelic approved as a prescription medicine in the United States. That approval, combined with the Trump executive order’s rescheduling pathway, would change the legal landscape more dramatically than any state ballot measure could — because FDA approval creates a framework for prescribing that operates across all fifty states regardless of individual state law.

The map is moving. It is moving faster than most people outside the psychedelic space realize, and faster than it has moved at any point since these substances were first scheduled in 1970. Where you live still matters enormously right now — the difference between Oregon and Florida is the difference between legal supervised access and criminal prosecution. But the gap between those two positions is narrowing, and the forces narrowing it are no longer countercultural. They are clinical, legislative, and increasingly, presidential.